Loading
Diabetes and Associated Disorders / Salivary Gland Disorders and Functions · Journal article
Frontiers in Immunology · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This bioinformatic study integrated gene expression databases to identify ZBTB16 as a shared molecular marker in primary Sjögren's syndrome and type 1 diabetes, supported by experimental validation showing reduced ZBTB16 expression and altered NK cell frequencies in NOD mice. The work is mechanistic and exploratory, establishing a biological hypothesis linking the two autoimmune conditions but providing no evidence of clinical diagnostic or therapeutic utility in human populations.
Bioinformatic discovery study with experimental validation in animal model. Gene expression data from patients with primary Sjögren's syndrome and type 1 diabetes mellitus from public databases; non-obese diabetic mice for experimental validation. Intervention: ZBTB16 expression and associated immune-metabolic signatures in disease states.
ZBTB16 identified as shared hub biomarker in both pSS and T1DM with favorable diagnostic performance by ROC analysis Significantly reduced ZBTB16 expression confirmed in peripheral blood mononuclear cells, salivary gland tissues, and pancreatic tissues of NOD mice Resting NK cells positively correlated with ZBTB16 expression in computational analysis of both diseases
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work identifies a mechanistic link between two autoimmune conditions but does not yet provide evidence to guide clinical diagnosis or treatment. Further validation in human cohorts with clinical endpoints is needed before ZBTB16 can be considered for diagnostic application.
Bioinformatic discovery study with experimental validation in animal models identifying a shared biomarker, but no clinical diagnostic or therapeutic evidence in human subjects.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies a mechanistic link between two autoimmune conditions but does not yet provide evidence to guide clinical diagnosis or treatment. Further validation in human cohorts with clinical endpoints is needed before ZBTB16 can be considered for diagnostic application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Primary Sjögren’s syndrome (pSS) and type 1 diabetes mellitus (T1DM) share immune-inflammatory features, yet conserved pathogenic signatures linking these autoimmune disorders remain incompletely understood. The present research sought to uncover common molecular markers and dissect the underlying immune-metabolic cross-talk underlying pSS and T1DM. Methods Gene expression profiles of patients with pSS and T1DM were retrieved from the Gene Expression Omnibus database, normalized, and corrected for batch effects prior to downstream analyses. Overlapping potential biomarkers were screened by integrating differential expression analysis, weighted gene co-expression network analysis and least absolute shrinkage and selection operator regression. Functional enrichment based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases was implemented to interpret gene biological properties, and a protein–protein interaction network was further established afterwards. Diagnostic performance was evaluated using receiver operating characteristic analysis. Experimental validation was conducted in non-obese diabetic (NOD) mice using quantitative PCR, immunohistochemistry, and flow cytometry. The CIBERSORT algorithm was adopted to quantify immune cell infiltration levels. Results ZBTB16 was identified as a shared hub biomarker in both pSS and T1DM and exhibited favorable diagnostic performance. Experimental validation confirmed significantly reduced ZBTB16 expression in peripheral blood mononuclear cells, salivary gland tissues, and pancreatic tissues of NOD mice. Gene Set Enrichment Analysis indicated that ZBTB16 -associated signatures were enriched in mitochondrial-related processes, neuroactive ligand-receptor interactions, and ribosome-related pathways. Immune infiltration analysis revealed that resting natural killer (NK) cells were positively correlated with ZBTB16 expression in both diseases. Flow cytometric analysis further confirmed a reduced proportion of resting NK cells in peripheral blood of NOD mice, consistent with the CIBERSORT-based prediction. Conclusion This study identifies ZBTB16 as a shared biomarker linking pSS and T1DM. Reduced resting NK-cell abundance was consistently observed in both computational and experimental analyses, and bioinformatic correlation analysis suggested a positive association with ZBTB16 expression. These findings provide evidence for shared molecular and immunological signatures underlying the two autoimmune disorders and support further investigation of the biological role and diagnostic value of ZBTB16 in pSS and T1DM.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.